Compare LQDA & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | RDNT |
|---|---|---|
| Founded | 2004 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.8B |
| IPO Year | 2020 | 1996 |
| Metric | LQDA | RDNT |
|---|---|---|
| Price | $68.52 | $73.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $41.00 | ★ $82.80 |
| AVG Volume (30 Days) | ★ 1.5M | 633.7K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | $158,320,000.00 | ★ $1,616,630,000.00 |
| Revenue This Year | $278.87 | $22.78 |
| Revenue Next Year | $57.13 | $10.70 |
| P/E Ratio | $54.56 | ★ N/A |
| Revenue Growth | ★ 1031.18 | 13.05 |
| 52 Week Low | $21.15 | $50.82 |
| 52 Week High | $93.61 | $85.84 |
| Indicator | LQDA | RDNT |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 52.91 |
| Support Level | $30.48 | $73.73 |
| Resistance Level | $92.35 | $74.55 |
| Average True Range (ATR) | 3.20 | 2.43 |
| MACD | -0.54 | -0.66 |
| Stochastic Oscillator | 22.32 | 9.63 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.